NTRA vs UTHR
Natera, Inc. vs United Therapeutics — AI-powered side-by-side comparison
VS
UTHR
United Therapeutics
72
Buy
| Metric | NTRA | UTHR |
|---|
| AI Score |
65
|
72
|
| Price |
$312.59
|
$514.89
|
| P/E Ratio |
-229.94×
|
17.05×
|
| ROE |
-12.2%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
65.3%
|
86.1%
|
| Debt / Equity |
0.12×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
71.1
|
52.2
|
| Beta |
1.514
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for NTRA versus UTHR.
UTHR leads by 7 points.
UTHR scores 72/100 (Buy) versus NTRA at 65/100 (Buy).
NTRA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Revenue growing 37.8% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 18.5x prices in significant intangible value — Value
- ROE of only -11.7% -- cheap may mean cheap for a reason — Value
- RSI at 71 is in overbought territory — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.